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Abstract
Acute kidney injury is a very relevant feature in the liver cirrhosis. Acute renal failure 
is due to prerenal factors, intrinsic factors of the kidney, or postrenal. Prerenal damage 
is the result of renal hypoperfusion without damage to the glomeruli or renal tubules. 
Without treatment, prerenal acute renal failure can progress to acute tubular necrosis, 
a type of intrinsic renal damage. Patients with cirrhosis are prone to developing acute 
kidney injury. The acute decrease of the kidney function contributes to the mortality of 
patients with cirrhosis. The potential triggers of acute kidney injury should be recog-
nized and removed; this includes the discontinuation of diuretics and nephrotoxic drugs, 
the treatment of infections and gastrointestinal bleeding, and plasma expansion in case 
of hypovolemia. The new International Club of Ascites-Acute Kidney Injury in cirrhosis 
criteria provide a simple and relevant staging system for acute kidney injury in patients 
with liver cirrhosis based on relative increases in serum creatinine. Vasopressors such as 
terlipressin and norepinephrine in combination with intravenous albumin represent the 
first-line therapy for hepatorenal syndrome.
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1. Introduction
The association of acute kidney injury (AKI) in patients with liver cirrhosis has been estab-
lished in the context of the hepatorenal syndrome, but there are several etiologies besides 
this cause.
Acute renal failure is a therapeutic challenge in patients with liver cirrhosis. This may be 
related to abnormal hemodynamics with systemic arterial vasodilatation and the splanchnic 
bed, in addition to the vasoconstriction of extrahepatic vessels, characteristic of advanced 
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liver cirrhosis [1]. Acute renal failure frequently occurs in the advanced stages of liver cir-
rhosis and entails a bad prognosis [2, 3].
Acute renal failure is due to prerenal factors, intrinsic factors of the kidney, or postrenal. 
Prerenal damage is the result of renal hypoperfusion without damage to the glomeruli or 
renal tubules. Without treatment, prerenal acute renal failure can progress to acute tubular 
necrosis (ATN), a type of intrinsic renal damage.
The prevalence of acute renal failure in cirrhosis has been reported from 14 to 50% in patients 
with cirrhosis. Its prevalence is approximately 50% in patients with cirrhosis and ascites and 
20% of patients with advanced stage cirrhosis who are hospitalized [4, 5].
The definition of acute kidney injury is a reduction in the glomerular filtration rate (GFR) 
over a short time of period, and this is a common and severe complication in the patients with 
liver cirrhosis. Acute kidney failure can be triggered by a precipitating event, for example, 
overdose of diuretics, gastrointestinal bleeding, large-volume paracentesis without albumin 
replacement, bacterial infections, and so on [6]. The prevalence of acute kidney injury is 
approximately 20–50% among hospitalized patients with cirrhosis [6–9] and the renal failure 
development is more common in patients with cirrhosis compared to individuals without 
liver disease [10]. The presence of acute kidney failure is associated with poor prognosis in 
these patients and represents an important predictor for short-term mortality [11].
The criteria for acute renal failure in cirrhosis were initially proposed in 1996 [12] and rede-
fined in subsequent years [13]. Traditionally, renal failure in cirrhosis was defined as a 50% 
increase in serum creatinine, with an increase greater than 1.5 mg/dL (133 μm/L) of it. The 
cutoff value of serum creatinine to define acute renal failure in patients with decompen-
sated cirrhosis has changed [14, 15]. Several nephrology academic societies have proposed 
the use of the concept of acute renal injury to represent acute changes in kidney function. 
The diagnostic criteria constitute a combination of changes in the glomerular filtration rate 
as well as a reduction in urine output. In the past decade, the definition of acute kidney 
injury evolved to the classifications and diagnostic criteria known as RIFLE [16], AKIN [17], 
and KDIGO [18].
In 2010, the International Ascites Club (IAC) and the Acute Dialysis Quality Initiative (ADQI) 
decided to use the nomenclature of the Acute Kidney Injury (AKI).
In 2015, the International Ascites Club established a new definition and staging of acute renal 
failure for patients with liver cirrhosis [19].
2. Physiopathology of renal failure in cirrhosis
Patients with liver cirrhosis develop portal hypertension, which results in the vasodilatation 
of the splanchnic vascular bed, resulting in blood accumulation due to resistance in the portal 
venous flow. This is due to an increase in the fixed resistance of liver fibrosis, and dynamics 
in the splanchnic arteries is last due to
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a. vasodilators such as nitric oxide, carbon monoxide, and endogenous cannabinoids 
[20, 21];
b. vasodilation by pro-inflammatory cytokines such as tumor necrosis factor and interleukin 
6, derived from bacterial translocation of the intestine [22].
The accumulation of blood in the splanchnic bed leads to a reduction in the effective circulat-
ing volume, which leads to a compensatory increase in cardiac output through the activation 
of the sympathetic nervous system by the carotid baroreceptors in order to maintain adequate 
renal perfusion [23].
In advanced stages of cirrhosis, systemic vascular resistance is significantly reduced, and 
the additional increase in cardiac output cannot compensate. Thus, it is evident that cardiac 
output decreases as cirrhosis progresses. In advanced stages of cirrhosis, cardiac output is 
maintained through the activation of vasoconstrictor systems, including the sympathetic 
nervous system and the renin-angiotensin system, and by a non-osmotic hypersecretion of 
arginine-vasopressin.
These compensatory mechanisms can help to maintain effective arterial volume and of this 
way a relatively normal blood pressure, but this has important effects on kidney function, 
primarily a retention of water and sodium, which can eventually lead to the formation of 
ascites and edema, and renal failure conditioned by renal vasoconstriction and hypoperfusion 
[24, 25].
There are four factors involved in the pathogenesis of hepatorenal syndrome. These are the 
following:
1. Activation of the renin-angiotensin-aldosterone system and the sympathetic nervous 
system which causes renal vasoconstriction and a shift in the renal autoregulatory curve, 
which results in a renal blood flow more sensitive to changes in the arterial pressure.
2. Splanchnic vasodilatation, which causes a fall in the effective arterial blood volume and 
this way a decrease of the mean arterial pressure.
3. Increased synthesis of vasoactive mediators which affect renal blood flow or glomerular 
microcirculatory hemodynamics, such as leukotrienes, thromboxane A2, isoprostanes, and 
endothelin-1.
4. Impairment of cardiac function due to the development of cirrhotic cardiomyopathy, 
which leads to a relative impairment of the compensatory increase in cardiac output sec-
ondary to vasodilatation.
Hemodynamic disorders can have widespread impact on the body according to the severity 
of the cirrhosis [26]. The hemodynamic changes in cirrhosis include portal hypertension and 
hyperdynamic circulation which are the main cause of morbidity and mortality in patients 
with cirrhosis. The effective arterial blood volume and the circulating levels of RAS com-
ponents and antidiuretic hormone remain normal at early stages of the disease, even with a 
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reduced systemic vascular resistance. The elevated cardiac output and low systemic vascular 
resistance are characteristics of the portal hypertension and hyperdynamic circulation in cir-
rhosis. Arterial vasodilation in the splanchnic circulation and the resulting decrease in sys-
temic vascular resistance are associated with portal hypertension in cirrhosis. Compensatory 
mechanisms following the reduction of systemic vascular resistance lead to hyperdynamic 
circulation. Nevertheless, hyperdynamic circulation is insufficient to correct the effective arte-
rial hypovolemia when the disease progresses and arterial vasodilation increases, resulting in 
arterial hypotension and consequent activation of the circulating renin-angiotensin-aldosterone 
system and the sympathetic nervous system and secretion of antidiuretic hormone [27].
In the early stages of disease, the circulating RAS is not activated at early stages of the disease. 
The patients at the advanced stages of cirrhosis presented an activation of peripheral and 
splanchnic renin-aldosterone system, and a metabolic deviation toward the RAS vasodilator 
axis in the splanchnic circulation (Figure 1).
2.1. Causes of acute kidney injury in cirrhosis
The acute kidney injury has prerenal, intrarenal, or postrenal causes (Figure 2). The most com-
mon causes of acute kidney injury between patients with cirrhosis are the prerenal etiologies, 
followed by acute tubular necrosis, and the postrenal etiology is extremely rare. The prerenal 
and acute tubular necrosis are the etiology of 80% of cases (49% prerenal and 35% acute tubular 
Figure 1. Hemodynamic alterations in the early and advanced stages of cirrhosis. In the early stages of cirrhosis, there 
is an increased cardiac output and a diminished systemic vascular resistance without changes in the circulating levels 
of the renin-angiotensin system components and antidiuretic hormone. In later phases of the cirrhosis, the components 
of the renin-angiotensin-aldosterone system are elevated, with activation of the sympathetic nervous system and 
secretion of the antidiuretic hormone, like a response to persistent arterial hypotension. Ang II: angiotensin II; Ang-(1–7): 
angiotensin (1–7); SNS: sympathetic nervous system; SVR: systemic vascular resistance.
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necrosis). Postrenal injury accounted for only 0.2%. In a prospective study, among patients with 
cirrhosis listed for liver transplantation who had acute kidney injury, prerenal injury was the 
most common cause in 76% followed by intrarenal etiology in 33%, while postrenal etiology did 
not occur in any patient [66, 67].
3. Prerenal injury
3.1. Volume responsive prerenal AKI
The hemodynamic state in cirrhosis with vascular dilatation and reduced vascular resis-
tance in cirrhosis is quite similar to hemodynamic state in sepsis, especially spontaneous 
bacterial peritonitis. Prerenal injury occurs commonly due to gastrointestinal bleeding, 
infections, use of diuretics, diarrhea often related to lactulose use for hepatic encepha-
lopathy, and from large-volume paracentesis without albumin infusion. Large-volume 
paracentesis may be associated with intravascular volume depletion and acute kidney 
failure. This condition occurs in up to 70% of patients undergoing paracentesis when more 
Figure 2. Management approach and algorithm for acute kidney injury in patients with cirrhosis. AKI, acute kidney 
injury; ESLD, end-stage liver disease; HRS, hepatorenal syndrome; LVP, large-volume paracentesis; RRT, renal 
replacement therapy; LTA, liver transplant alone; SLK, simultaneous liver kidney; TIPS, transjugular intrahepatic 
portosystemic shunt; USG, ultrasonogram.
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than 5 L are removed and albumin is not infused. The use of any drugs like NSAIDs 
can precipitate acute kidney failure by decreasing renal prostaglandins and accentuating 
the intrarenal vasoconstriction and further decrease renal blood flow. The advice to the 
patients should be provided to avoid these drugs for the management of pain. The use of 
intravenous contrast agents in patients with cirrhosis is another potential risk factor for 
acute kidney failure. The infections have common occurrence in patients with cirrhosis. 
Hence, superimposed infections/sepsis in cirrhosis patients worsen this physiology, caus-
ing a reduction of circulating blood volume and leading to the development of AKI. Before 
the widespread use of antibiotic prophylaxis for acute gastrointestinal bleeding in cir-
rhosis, more than 20% of patients with cirrhosis hospitalized for acute gastrointestinal 
bleeding had a bacterial infection present on admission, with up to 50% developing an 
infection while hospitalized.
3.2. Volume nonresponsive prerenal AKI: hepatorenal syndrome
The volume expansion is the first treatment after acute kidney failure is diagnosed, using 
crystalloids or intravenous albumin and discontinuation of precipitating medications. If 
renal function does not normalize or improve with this intervention, it is important to con-
sider hepatorenal syndrome (HRS) in the differential diagnosis to consider as the cause for 
AKI. HRS is a functional form of renal failure without any major structural or histological 
changes in the kidneys that is characterized by intense renal vasoconstriction. It is important 
to differentiate it from another intrarenal cause, because management and prognosis differ. 
In the absence of renal biopsy, the diagnosis of HRS remains difficult and is essentially a 
diagnosis of exclusion. In patients with cirrhosis, HRS develops in about 18% at 1 year and 
39% at 5 years.
Approximately, 66% of all HRS cases are type 2, or HRS-AKI which are rapidly occurring 
with an increase in serum creatinine to over 2.5 mg/dL over 1 or 2 weeks. Type 1 HRS has 
high mortality with a median survival of around 50% at 2 weeks and is usually precipitated 
by infections. The type 2 HRS has a better outcome with a median survival of about 6 months 
and a slower course in the setting of refractory ascites, with slowly increasing serum creati-
nine to over 1.5 mg/dL. The definition of type I HRS has been recently revised and changed 
the value of 2.5 mg/dL serum creatinine for diagnosis, thus avoid delaying the initiation of 
therapy.
3.3. Volume nonresponsive intrinsic AKI: acute tubular necrosis
The most common cause for intrarenal AKI in cirrhosis is ATN. This occurs commonly either 
as a complication of sepsis or due to unrecognized and untreated prerenal injury. The main 
cause of ATN has been attributed to sepsis, followed by hypovolemia and rarely nephrotoxic 
drugs.
Other less common causes of intrarenal injury include tubular damage due to bile cast 
nephropathy from high-conjugated bilirubin excreted through the glomeruli, membranopro-
liferative glomerulonephritis with or without cryoglobulinemia associated with hepatitis C, 
and acute interstitial nephritis due to medications, such as antibiotics, NSAIDS, and proton 
pump inhibitors.
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4. Postrenal injury
As stated earlier, postrenal injury is a rare cause of AKI in cirrhosis [66, 68]. This etiology can 
easily be excluded using renal ultrasound or CT scan.
4.1. Evaluation of the renal function
The glomerular filtration rate (GFR) is the universally used index to quantify kidney function. 
The principle of GFR determination is to determine the body clearance of a substance with the 
supposed exclusive renal clearance. The substance used for determinate GFR must be freely 
filtered and neither reabsorbed or secreted along the renal tubule. Also, no extrarenal excre-
tion of the substance occurs, and it cannot be stored or be bound to plasma proteins: then it 
can be assumed that the plasmatic clearance is only due to renal clearance. Thus, the GFR can 
be inferred from the plasma disappearance of the substance. It is considered that the renal 
clearance of a marker occurs only through glomerular filtration [28].
Calculation of the eGFR requires normalization to BSA. Studies that tested the performance 
of this method showed a clear trend to overestimate mGFR by 4–80%. A normalization based 
on the assumption that the GFR is positively correlated with the basal metabolism rate of 
individuals which is proportional to their stature on arbitrarily fixed body surface area (BSA) 
set to 1.73 m2 is commonly done [29]. This normalization has been questioned [30] and stan-
dardization on other criteria has been proposed [31]. The formula most commonly used to 
determine the BSA is the Dubois formula, and the adjustment on the body surface remains 
widely used [32].
Historically, the Cockcroft and Gault formula was the most popular before the MDRD for-
mula was published in the early 2000s. This formula is not adjusted to the patient BSA, and 
the adjustment has, theoretically, to be done afterwards (even if the relevance of this adjust-
ment remains to be assessed in cirrhotic patients). The relationship between GFR level and 
overestimation could be explained by the secretion of creatinine by the tubule in patients 
with CKD. However, the importance of this overestimation does not seem to be related to the 
severity of cirrhosis.
Creatinine clearance is a simple method to estimate GFR, based on the assumption that cre-
atinine has the characteristics of a perfect renal marker. It requests the accurate recollection 
of urine from a 24-h period. It has several limitations: mainly, the possible inadequate urine 
collection by the patients, the occurrence of tubular secretion of creatinine, which leads to 
overestimation of the GFR, and that is on a longer or a shorter than 24-h time period.
4.2. Definition of acute kidney injury in cirrhosis
The definition of acute kidney injury in cirrhosis consists in an acute increase in serum creatinine 
of >0.3 mg/dL in a time lapse of 48 h or by <50% from a stable baseline serum creatinine, in the 
last 3 months (presumed to have developed within the past 7 days when no prior readings are 
available) [19, 33]. In addition, the use of urine output as part of the diagnostic criteria was elimi-
nated, since many patients with cirrhosis and ascites maintain a preserved renal function despite 
being oliguric due to sodium and water retention. The main modifications over the previous, 
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rather stringent, criteria that were based on absolute serum creatinine level, were abandoning 
the threshold of serum creatinine >1.5 mg/dL to diagnose acute kidney injury, because milder 
degrees of renal failure in cirrhotic patients had often remained underdiagnosed [34, 35].
Similar to the ICA-AKI criteria, most of these studies diagnosed AKI solely on serum creati-
nine. In 2013, a modified, AKIN-derived score for cirrhosis was developed, by division of AKI 
stage 1 into two groups depending on whether or not serum creatinine surpassed the thresh-
old of 1.5 mg/dL and by merging AKI stages 2 and 3 into stage “C” [40]; this reclassification 
did not gain wide acceptance. Several clinical studies have evaluated the prognostic value of 
the AKIN/KDIGO criteria that constitute the basis for the International Club of Ascites (ICA)-
AKI criteria in patients with cirrhosis [37–39]. The acute kidney injury can be classified into 
three stages according to severity. Stage 1 AKI is defined by rather small changes in serum 
creatinine, while stages 2 and 3 AKI are defined by a twofold and threefold increase in serum 
creatinine, respectively (Table 1) [36]. Since their publication in 2015, the newer and cirrho-
sis-specific ICA criteria have been assessed within one retrospective study in hospitalized 
patients with cirrhosis [41]. Within this study, approximately 40% of patients experienced 
AKI during their hospitalization with the majority of cases having been diagnosed at stage 1. 
Also, in patients with AKI stage 1 and a serum creatinine of <1.5 mg/dL, already a 3.5-fold 
increase in 30-day mortality as compared to patients without AKI was reported [41], again 
underlining the prognostic importance of even small increases in serum creatinine levels.
4.3. Hepatorenal syndrome type of acute kidney injury or type 1 hepatorenal 
syndrome
Hepatorenal syndrome (HRS) is defined as the occurrence of renal failure in a patient with 
advanced liver disease in the absence of an identifiable cause of renal failure [12].
The hepatorenal syndrome type I requires the fulfillment of several specific diagnostic criteria 
that are summarized in Table 2. This Acute Kidney Injury (HRS-AKI) is defined as >stage 2 
ICA-AKI that is diagnosed after other causes of renal failure have been ruled out [35].
Table 1. Criteria of AKI of the International Club of Ascites [36].
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The Guidelines of the European Association for the Study of Liver Diseases (EASL) and the 
American Association for the Study of the Liver (AASLD) Clinical Practice Guidelines for 
ascites and hepatorenal syndrome still proclaim the threshold of 2.5 mg/dL for diagnos-
ing HRS-AKI [42, 43]. The use of this threshold in clinical practice would mean that proper 
diagnosis and treatment of HRS would be withheld as long as serum creatinine does not 
reach this threshold. In order to prevent misclassification or even treatment delay, the newer 
International Club of Ascites criteria focus on the relative increase in creatinine rather than 
absolute values, since also smaller rises in serum creatinine have been shown to have a nega-
tive prognostic impact in patients with cirrhosis [44].
The hepatorenal syndrome is classified in two types. HRS type 1 is a quickly progressive acute 
renal failure. It commonly occurs in patients with end-stage cirrhosis following a septic insult 
such as spontaneous bacterial peritonitis or severe alcoholic hepatitis; this kind of hepatorenal 
syndrome frequently is developed in temporal relationship with a precipitating factor for a 
deterioration of liver function together with a deterioration of other organ function, although 
it may occur in the absence of any identifiable triggering event. Type 1 HRS is only diagnosed 
when the serum creatinine increases more than 100% from baseline to a final level of greater 
than 2.5 mg/dL.
Patients with type 2 HRS may eventually develop type 1 HRS; this can be spontaneously or 
following a precipitating event such as an infection [12].
HRS should be diagnosed and excludes other known causes of renal failure and by dem-
onstrating a significant increase in serum creatinine. For practical purposes, HRS is usually 
diagnosed only when serum creatinine increases to >133 mol/L (1.5 mg/dL). Repeated mea-
surement of serum creatinine over time, particularly in hospitalized patients, is helpful in the 
early identification of HRS.
The diverse etiologies of renal failure in cirrhosis should be excluded before to conclude 
the diagnosis of HRS. Parenchymal renal diseases should be suspected if there is significant 
Table 2. Diagnostic criteria for hepatorenal syndrome [12].
Acute Kidney Injury in Cirrhosis
http://dx.doi.org/10.5772/intechopen.78571
39
proteinuria or micro-hematuria, or if renal ultrasonography demonstrates abnormalities in 
kidney size. The hypovolemia, shock, parenchymal renal diseases, and concomitant use of 
nephrotoxic drugs are common causes of acute kidney injury and must be excluded before to 
diagnose HRS. Renal biopsy is important in these patients to help plan the further manage-
ment, including the potential need for combined liver and kidney transplantation [42].
4.3.1. Treatment
The initial management of acute kidney injury should focus on the early recognition and cor-
rection of potential trigger events and on preventing further hemodynamic deterioration [25, 
33, 45]. In volume-depleted patients, diuretic therapy and/or lactulose should be withdrawn 
and plasma volume should be expanded with albumin, or blood transfusions in anemic 
patients due to gastrointestinal blood loss, is important the careful review of all medications, 
and consider the withdrawn of nephrotoxic agents. The use of medications that may induce 
or aggravate arterial should be carefully evaluated [46, 47].
Bacterial infections are a common precipitant of acute kidney injury, including the hepatore-
nal syndrome; in cirrhosis, these patients should be thoroughly screened for. The early initia-
tion of empiric antibiotic treatment based on clinical suspicion and the local epidemiology 
and resistance patterns must be considered [48, 49].
The therapeutic response is defined as a decrease of creatinine in serum to a value within 
0.3 mg/dL of baseline; in this case, the patients should be followed up closely for the early 
detection of recurrent episodes kidney failure. It is necessary to consider the possibility of 
hepatorenal syndrome In case of stage 2 or 3 or progression to a higher acute kidney injury 
stage, diuretics should be withdrawn immediately. The patients should receive plasma vol-
ume expansion with albumin for 2 consecutive days (1 g per kg of body weight, maximum 
100 g/day). Albumin is particularly beneficial in patients with sepsis because in addition to 
its volume-expanding effect, it has antioxidant, scavenging, and endothelial-stabilizing func-
tions [50]. A follow-up assessment of creatinine every 2–4 days during hospitalization and 
every 2–4 weeks during the first 6 months after discharge is advised [35].
In stages 2 and 3, the patients who meet diagnostic criteria of HRS-AKI should be treated 
with vasoconstrictors in combination with albumin [35]. The albumin initial dose is 1 g/kg 
body weight up to 100 g on the first day, then ongoing with 20–40 g/day, as it has been shown 
that the effects of intravenous albumin in the prevention and treatment of HRS are dose-
dependent, with better results when higher cumulative doses were administered [51, 52]. In 
all large-volume paracentesis (>5 L, with 8 g/L of ascites removed), albumin should be admin-
istered since it prevents post-paracentesis circulatory dysfunction, which reduces the risk of 
renal dysfunction and improve survival [53, 54].
The first-line drug therapy of type 1 hepatorenal syndrome is the use of terlipressin (1 mg/4–6 h 
intravenous bolus) in combination with albumin. The therapeutic target improves renal func-
tion enough to decrease serum creatinine to less than 133 mol/L (1.5 mg/dL); this is considered 
a complete response. If serum creatinine does not decrease at least 25% after 3 days, the dose of 
terlipressin should be increased in a stepwise manner up to a maximum of 2 mg/4 h. For patients 
with partial response (serum creatinine does not decrease <133 mol/L) or in those patients with-
out reduction of serum creatinine, treatment should be discontinued within 14 days.
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The terlipressin is the most intensively studied vasoconstrictor for the treatment of HRS-
AKI. A bolus of terlipressin induces a significant reduction in the portal pressure for over a 
3- to 4-h period and also increases the mean arterial pressure [55]. Hyponatremia must be 
considered, and this commonly occurs in less advanced liver disease and normal baseline 
serum sodium levels [56, 57]. Considering the pharmacodynamic profile and the costs of 
terlipressin, continuous infusion might be preferred over bolus administration. Although 
terlipressin has been consistently shown to improve renal function, its impact on survival 
is less clear [58]. Terlipressin is particularly beneficial in patients with sepsis and might 
also prevent variceal bleeding during the period of discontinuation of nonselective beta 
blockers [59].
Norepinephrine is an alternative to the use of terlipressin with an initial dose: 0.5 mg/h, and 
a max. Dose studied in randomized controlled trials of 3 mg/h, norepinephrine is equally 
effective and inexpensive. A meta-analysis of four randomized-controlled trials demonstrated 
similar efficacy for HRS, when compared to terlipressin [60]. The therapy recommended for 
type 2 hepatorenal syndrome is similar [61, 62]; however, HRS type 2 commonly recurs after 
termination of treatment with vasoconstrictors [63].
Complete response is defined by a decrease in serum creatinine to a value within 0.3 mg/dL of 
baseline, while a regression of at least one AKI stage is considered as partial response [35]. If 
there is no response after 3 days of treatment, the vasoconstrictor dose should be increased. In 
nonresponders, treatment should be discontinued after 14 days. In responders, longer treat-
ment durations can be used as a bridging therapy to liver transplantation.
Potential alternative therapies to terlipressin include norepinephrine or midodrine plus 
octreotide, both in association with albumin, but there is very limited information with respect 
to the use of these drugs in patients with type 1 HRS. Treatment with terlipressin should be 
repeated and is frequently successful. The recurrence of type 1 HRS after discontinuation of 
terlipressin therapy is relatively uncommon.
Cardiovascular ischemic disease is a contraindication to terlipressin therapy. Patients on 
terlipressin should be carefully monitored for signs of splanchnic or digital ischemia, the 
development of cardiac arrhythmias and fluid overload, and treatment modified or stopped 
accordingly.
The use of TIPS may improve renal function in some patients; there are insufficient data in 
patients with type 1 HRS to support the use of TIPS as a treatment. The renal replacement 
therapy may be useful when the patients do not respond to vasoconstrictor therapy. There 
are limited data on the use of artificial liver support systems, and further studies are required 
for its use [43].
4.4. Hepatitis C and acute kidney injury
Hepatitis C (HCV) infection can induce kidney injury, mainly due to the formation of immune 
complexes and cryoglobulins, and possibly to a direct cytopathic effect. HCV is responsible 
for membranous glomerulonephritis or mesangiocapillary and accelerates the progression of 
chronic kidney disease due to other causes. It may cause acute kidney injury as a part of systemic 
vasculitis and augments the risk of AKI due to other etiologies. HCV-infected patients are at an 
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increased risk of acute posttransplant complications. HCV infection increases cardiovascular 
and liver-related mortality in patients on regular dialysis. Long-term graft survival is compro-
mised by chronic transplant glomerulopathy or recurrent or de novo glomerulonephritis. The 
increased incidence of diabetes, sepsis, posttransplant lymphoproliferative disease, and liver 
failure compromises the patient survival. Directly acting antiviral agents (DAAs) are currently 
available for treatment at different stages of kidney disease. It is concluded that the thoughtful 
use of DAAs will result in a significant change in the epidemiology and clinical profiles of kid-
ney disease, as well as improvement of dialysis and transplant outcomes, in endemic areas [64].
The acute kidney failure induced by HCV is a systemic disease reported in <5% of HCV-
infected (HCV+ve) patients. It is characterized by multiorgan involvement, mainly affecting 
the lungs and kidneys, skin, musculoskeletal system, and peripheral nerves. The fundamental 
lesion is endothelial injury, perivascular inflammation with lymphocytic and neutrophilic 
infiltration, small vessel necrosis, and luminal occlusion by cryoglobulins and fibrin thrombi.
4.5. Cryoglobulinemic vasculitis
In the kidneys, this leads to focal fibrinoid necrosis of the glomerular tufts, often with crescent 
formation (Figure 3). The renal tubules are affected by ischemic and inflammatory lesions 
and contain hyaline and blood casts. The ureteric and bladder mucosa may display vasculitic 
purpuric lesions. The interstitium is infiltrated with inflammatory cells and found edematous.
The mechanism of vascular injury is typically attributed to component C1q of the complement, 
complement activation generates chemotactic factors, C3a and C5a, which recruit and activate 
pro-inflammatory leucocytes. It also leads to the formation of C5–9, the membrane attack com-
plex that may have an important role in endothelial damage, the active complement compo-
nent incorporated within the cryoglobulin complex. This leads to endothelial injury by dual 
effects, namely the activation of the complement cascade via the classical pathway and binding 
to endothelial complement receptors, thereby localizing the injury in target capillary beds.
The clinical presentation has a wide range from isolated hematuria to acute kidney injury, 
sometimes associated with thrombotic microangiopathy (Figure 4). If left untreated, the 
Figure 3. Cryoglobulinemic renal vasculitis. Renal arteriole showing endothelialitis and cryoglobulin deposits in a 
patient with AKI due to HCV-associated cryoglobulinemia. Hematoxylin and eosin stain. Reproduced with permission 
from Ref. [64].
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prognosis becomes bad for the renal function, as well as patient survival. The successful treat-
ment may lead to complete or partial recovery, unless the damage has already been extensive, 
leading to healing with focal or global sclerosis.
4.6. Non-cryoglobulinemic AKI
HCV-infected patient, compared to the general population are at many-fold risk of devel-
oping acute kidney injury of diverse etiology. The most frequent cause of kidney injury is 
hypovolemia associated with excessive vomiting or diarrhea. The second common cause 
was bacterial infection in the lungs, urinary, or gastrointestinal tract; 7.3% of patients had 
advanced cirrhosis and developed AKI following an episode of hematemesis, presumably 
due to ischemic acute tubular necrosis, and 6.5% were associated with hepatic encephalopa-
thy including the hepatorenal syndrome. Decompensated liver disease, diabetes mellitus, 
history of intravenous drug abuse, and high baseline serum creatinine were independent 
predictors of developing AKI. End-stage kidney disease eventually developed in 17.5% 
of patients who developed AKI, compared to 1% of those who did not. Risk factors for 
end-stage renal kidney disease were preexisting hypertension, diabetes, or chronic kidney 
disease [65].
5. Summary
Patients with cirrhosis are prone to developing acute kidney failure. The acute decrease of 
the kidney function contributes to the mortality of patients with cirrhosis. The criteria of the 
International Club of Ascites for acute kidney injury provide a simple and relevant staging 
system for acute kidney injury in patients with liver cirrhosis based on relative increases in 
serum creatinine. It is very important to consider the potential triggers of renal failure, and 
this should be recognized early and removed; this includes discontinuation of nephrotoxic 
drugs and diuretics, treatment of infections and gastrointestinal bleeding, and plasma expan-
sion in case of hypovolemia.
Figure 4. Blood smear in a patient with cryoglobulinemic vasculitis and thrombotic microangiopathy. Note the red cell 
fragmentation with microcytes and schistocytes.
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Cardiovascular ischemic disease is a contraindication to terlipressin therapy. Patients on 
terlipressin should be carefully monitored for signs of splanchnic or digital ischemia, the 
development of cardiac arrhythmias and fluid overload, and treatment modified or stopped 
accordingly.
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